This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amarantus BioSciences Announces Publication Of Positive Animal Data For MANF In Myocardial Infarction

SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction.  The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.

"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."

Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.

About Amarantus BioSciences, Inc.

 Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to diagnose and treat Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,011.94 -28.43 -0.16%
S&P 500 2,109.60 -2.13 -0.10%
NASDAQ 5,076.5240 -6.4050 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs